Hyderabad, India: Bioserve Biotechnologies India Pvt. Ltd. has entered into an exclusive distribution agreement with HLB PEP Co., Ltd. (Republic of Korea) for the Indian market. Under this agreement, Bioserve will begin distributing peptides manufactured by HLB PEP.
Bioserve is a leading provider of DNA synthesis and genetic analysis services in India. Since its establishment, the company has been manufacturing and selling oligonucleotide products, which are mainly supplied to public research institutions such as universities, biopharmaceutical companies, and other life science-related organizations in India.
Daisuke Usui, CEO of Bioserve, commented, “The addition of HLB PEP’s peptides to our product range will create significant synergies with our current operations, delivering mutual benefits and enhanced value for our customers.”
About HLB PEP Co., Ltd.
Founded in 2000, HLB PEP is a South Korea–based contract manufacturing organization (CMO) specializing in peptide synthesis for research and drug development. The company is recognized for its expertise, quality standards, and innovation in the peptide industry. It was the first Korean company to achieve GMP certification for peptide manufacturing and continues to produce high-quality peptides, including GMP-grade products, for global clients.
For more information, please contact:
info@reprocell.in